NMPA
China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
July 18, 2024Medical Communications China, Everest Medicines, NMPA, Nephrology
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …
NMPA approves CStone’s Cejemly for lymphoma treatment
October 31, 2023Medical Communications CStone, Cejemly, NMPA, Oncology, lymphoma
CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved its anti-PD-L1 antibody Cejemly (sugemalimab) …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
October 26, 2023Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …
China approves Astellas’ Xtandi in non-metastatic castration-resistant prostate cancer
November 6, 2020Medical Communications, Sales and Marketing Astellas, China, NMPA, Xtandi
China’s drug regulator, the National Medical Products Administration (NMPA), has given the green light to Astellas to market Xtandi (enzalutamide …
China approves first homegrown HPV vaccine
January 8, 2020Research and Development, Sales and Marketing China, HPV, NMPA, pharma, vaccines
Female patients in China between the ages of nine and 45 will have access to the country’s first domestically-produced vaccine …
Latest content
FibroFind appoints Lee Borthwick as CEO
